Blockchain Registration Transaction Record

Tonix's TONMYA Fibromyalgia Data to Be Presented at IASP 2026

Tonix Pharmaceuticals' TONMYA fibromyalgia data to be presented at IASP 2026. TONMYA is the first new fibromyalgia treatment in over 15 years.

The presentation of TONMYA data at the IASP 2026 World Congress on Pain underscores the growing recognition of fibromyalgia as a serious condition and the need for new treatment options. As the first new therapy for fibromyalgia in over 15 years, TONMYA's presence at a global pain conference signals hope for millions of patients who have long faced limited choices. For investors, this visibility could enhance Tonix's credibility and market position, potentially driving adoption and future growth. Moreover, the company's broader pipeline in CNS and immunology, including programs for major depressive disorder, acute stress disorder, Prader-Willi syndrome, Lyme disease prophylaxis, and kidney transplant rejection, demonstrates a commitment to addressing high unmet medical needs. This news matters because it highlights a significant step forward in pain management and showcases a company poised to make a meaningful impact on patients' lives.